

Mirati Therapeutics, Inc.

Vermont New Product Launch Report

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE
80739-0812-18	KRAZATI (adagrasib) tablets, 200 mg,180 count	12/21/2022

10 or 11 Digit NDC

This will include: Drug Trade Name,
Active Ingredient, Strength, and Size

Date Product was commercially
available

Key **Used for Full Report Due 30 Days After Initial Notice**

Submissions Made To AGO.highcostprescriptiondrugs@vermont.gov

WAC AT INTRODUCTION	MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC
\$ 19,750.00	There is no direct-to-consumer m	No
WAC on the date the Product was commercially available	A narrative description of the marketing and pricing plans used in the launch of the new prescription drug in the United States and internationally	Please respond with Yes or No

ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR
5000	Y	Y
The estimated number of patients in the United States with a condition for which the new prescription drug may be prescribed	Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval	Indicate whether the drug was granted breakthrough therapy designation or priority review by the federal Food and Drug Administration prior to approval

ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC
[Redacted]		

If this field in N/A then please leave blank

If this field in N/A then please leave blank

Please respond with Yes or No

ACQUISITION PRICE COMMENT	GENERAL COMMENTS

If this field in N/A then please leave blank

